Table 1.
Study | Population | Best response to TKIs | TKIs, response and PFS |
---|---|---|---|
Our case | East Asian | PR | Icotinib, PR, 4m; Osimertinib, PR, 21m |
Gallant et al. (1) | American | PR | Afatinib, PR, 10m |
Baik et al. (6) | American | PR | Gefitinib, PR, 6y; Erlotinib, PR, 3y |
Wiest et al. (7) | Germany | PR | Afatinib, PR, NA |
Zhu et al. (8) | East Asian | SD | Icotinib, SD, 11m (Not reach) |
Xu et al. (9) | East Asian | PR | Afatinib, PR, NA |
Wang et al. (3) | East Asian | SD | Icotinib, SD, NA |
Wang et al. (4) | East Asian | PD | Erlotinib, PD, 2m; Osimertinib, PD, 2m |
East Asian | PR | Gefitinib, PR, 5m; Afatinib, PD, 2m Osimertinib, PR, 4m (Not reach) |
|
East Asian | SD | Gefitinib, SD, 11m | |
East Asian | PR | Icotinib+apatinib, PR, 4m (Not reach) | |
East Asian | PD | Gefitinib, PD, 3m Erlotinib, PD, 5m |